Raxibacumab

Summary

Raxibacumab (CHEMBL2108638) is an approved antibody (ATC J06BC02); indicated across 1 condition including anthrax infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: J06BC02
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108638
Name	Raxibacumab
Type	Antibody
Max phase	4
ATC	J06BC02

Also known as: Abthrax, Raxibacumab, RAXIBACUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anthrax infection	4	MONDO:0005119	EFO:0000778

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02339155	PHASE4	COMPLETED	Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
NCT00639678	PHASE3	COMPLETED	A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
NCT02016963	PHASE2/PHASE3	COMPLETED	An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).